Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States, a National Cancer Database Analysis

ConclusionsThis is the largest study examining outcomes of patients with plasmacytoma using a large database analysis, revealing unique aspects of P-EM vs. P-bone and underutilization of radiation treatment.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsThis is the largest study examining outcomes of patients with plasmacytoma using a large database analysis, revealing unique aspects of P-EM versus P-bone and underutilization of radiation treatment.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This is the largest study examining outcomes of patients with plasmacytoma, using the National Cancer Data Base. Clinical and patient-related factors impacting overall survival were studied for both bone and extramedullary plasmacytoma. Patients with bone plasmacytoma who were treated at academic facilities had improved overall survival. Surprisingly, we found radiation treatment was underutilized in patients with solitary lesions, especially in those older than 75 years and with increasing distance from treatment facility.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
A higher risk for a variety of cancers is among the major complications of posttransplantation immunosuppression. In this part of a continuing series on cancers posttransplantation, this review focuses on the hematologic cancers after solid organ transplantation. Posttransplantation lymphoproliferative disorders (PTLDs), which comprise the great majority of hematologic cancers, represent a spectrum of conditions that include, but are not limited to, the Hodgkin and non‐Hodgkin lymphomas. The oncogenic Epstein‐Barr virus is a key pathogenic driver in many PTLD cases, through known and unknown mechanisms. The other hemat...
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: COMPREHENSIVE REVIEW Source Type: research
This article is protected by copyright. All rights reserved.
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: Comprehensive Review Source Type: research
Most of the studies of plasmacytoma are derived from small, single tertiary institution experiences. There is a paucity of large studies to assess real-world outcomes and survival patterns in this disease within the community.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
CTAs such as MAGE, NY-ESO-1 and CT7 are expressed in various types of tumors and in normal adult tissues only in testicular germ cells. Based on their tumor-associated expression pattern, CTAs are regarded as ideal vaccine targets for cancer immunotherapy. CTAs are highly expressed in various solid cancers such as melanoma as well as certain types of carcinomas and sarcomas but show little presence in most hematological malignancies. In plasma cell myeloma (PCM), however, single CTAs are highly expressed and show correlation with disease progression.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conditions:   Hematopoietic/Lymphoid Cancer;   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leuke...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Ac...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academia | Cancer | Cancer & Oncology | Databases & Libraries | Insurance | Leukemia | Lymphoma | Men | Myeloma | Plasmacytoma | Study | USA Health